Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
First and only PARP inhibitor to improve invasive disease-free survival in patients
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Acceptance based on results from the phase 3 KEYNOTE-091 trial
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Tislelizumab is now approved in nine indications in China
Subscribe To Our Newsletter & Stay Updated
